Moderna, INC Form 4 insider transactions

Moderna's Chief Financial Officer, James Mock, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Moderna President Stephen Hoge reported the conversion of restricted stock units into common stock and subsequent tax-related share disposals, alongside new equity awards.

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units, subsequent tax-related share dispositions, and the grant of new equity awards.

Moderna President Stephen Hoge executed a pre-planned sale of 160,009 shares of common stock following the exercise of stock options.

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of performance-based restricted stock units and subsequent tax-related share disposition.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the vesting of 2,630 performance-based restricted stock units and the sale of 1,334 shares for tax obligations.

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

An entity controlled by Moderna Director Noubar Afeyan exercised options and immediately sold 23,853 shares of Moderna common stock on December 11, 2025.

Moderna CEO Stephane Bancel exercised stock options to acquire 688,073 shares of common stock, paying over $13.4 million in cash.

Moderna Director Abbas Hussain sold 504 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units and subsequent sale of shares for tax obligations.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the vesting of 47,190 restricted stock units and the subsequent sale of 22,817 shares for tax obligations.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the conversion of restricted stock units into common stock and subsequent tax-related share disposals.

Moderna President Stephen Hoge reported the conversion of restricted stock units into common stock and the subsequent sale of shares to cover tax obligations.

Moderna's Chief Financial Officer, James M. Mock, reported the vesting of restricted stock units and subsequent sales of common stock to cover tax obligations.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported planned acquisitions of common stock from RSU conversions and subsequent tax-related dispositions under a 10b5-1 plan.

Moderna's President, Stephen Hoge, reported the vesting of restricted stock units and subsequent sales to cover tax obligations.

Moderna's CFO, James Mock, reported the conversion of restricted stock units into common stock and subsequent sale of shares for tax obligations.

Moderna Director Abbas Hussain disposed of 2,019 common shares following the vesting of 1,439 restricted stock units.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Moderna President Stephen Hoge reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Moderna's Chief Financial Officer, James M. Mock, reported the acquisition of common stock through RSU conversions and subsequent sales to cover tax obligations.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, filed a Form 4 detailing future acquisitions and dispositions of common stock related to RSU vesting.

Moderna President Stephen Hoge reported future acquisitions of common stock from RSU conversions and dispositions for tax withholding scheduled for late August 2025.

Moderna Director David M. Rubenstein acquired 850 shares of common stock through the vesting of restricted stock units.

Moderna's Chief Financial Officer, James M. Mock, reported the conversion of restricted stock units into common stock and subsequent sale of shares to cover tax obligations, as detailed in a recent Form 4 filing.

Moderna Director Abbas Hussain sold 312 shares of common stock on June 11, 2025, at $28 per share, to cover tax obligations arising from the vesting of restricted stock units.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the acquisition of 1,139 common shares from restricted stock unit vesting and the disposition of 551 shares for tax obligations on June 6, 2025, resulting in a beneficial ownership of 27,483 shares.

Moderna President Stephen Hoge reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the conversion of restricted stock units into common stock and subsequent share withholding for tax obligations.